Given the excitement and anticipation of increasingly more promising prophylactic treatments and gene therapies, the 2nd Annual Hemophilia Drug Development Summit, once again unites leading pharma, biotech and academic KOLs working to translate and clinically develop longer acting and more efficacious therapies to overcome significant unmet medical need and hemophilia and other bleeding disorders.
Attend the 2nd Hemophilia Drug Development Summit to identify novel drug development strategies and overcome the shared translational, clinical development and delivery challenges to dramatically improve patient outcomes.
Sounds interesting? Find out more – get free event brochure here: https://ter.li/4snxn9